Alexion has routinely featured among lists of top biopharma takeover prospects in the last couple of years, and that was a good call – AstraZeneca has just swooped in with $39 billion cash-and ...

Amgen has reported positive phase 3 results with its biosimilar version of AstraZeneca/Alexion's blockbuster rare disease drug Soliris, setting up a regulatory filing with the FDA. The biotech has ...

The £2.3 million CHART trial, set to launch in February 2025, will test the impact of Comprehensive Geriatric Assessment (CGA) in helping older ...

The eruption of neo-Nazism and White Supremacy across the country has exposed the public to symbols, terms, and ideology drawn directly from Nazi Germany and Holocaust-era fascist movements. The ...